COVID-19: vaccination vs. hospitalization.
BioNTech
COVID-19 pandemic
COVID-19 vaccine
SinoVac
Journal
Infection
ISSN: 1439-0973
Titre abrégé: Infection
Pays: Germany
ID NLM: 0365307
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
18
09
2021
accepted:
21
12
2021
pubmed:
6
1
2022
medline:
3
6
2022
entrez:
5
1
2022
Statut:
ppublish
Résumé
Vaccination is the most efficient way to control the coronavirus disease 2019 (COVID-19) pandemic, but vaccination rates remain below the target level in most countries. This multicenter study aimed to evaluate the vaccination status of hospitalized patients and compare two different booster vaccine protocols. Inoculation in Turkey began in mid-January 2021. Sinovac was the only available vaccine until April 2021, when BioNTech was added. At the beginning of July 2021, the government offered a third booster dose to healthcare workers and people aged > 50 years who had received the two doses of Sinovac. Of the participants who received a booster, most chose BioNTech as the third dose. We collected data from 25 hospitals in 16 cities. Patients hospitalized between August 1 and 10, 2021, were included and categorized into eight groups according to their vaccination status. We identified 1401 patients, of which 529 (37.7%) were admitted to intensive care units. Nearly half (47.8%) of the patients were not vaccinated, and those with two doses of Sinovac formed the second largest group (32.9%). Hospitalizations were lower in the group which received 2 doses of Sinovac and a booster dose of BioNTech than in the group which received 3 doses of Sinovac. Effective vaccinations decreased COVID-19-related hospitalizations. The efficacy after two doses of Sinovac may decrease over time; however, it may be enhanced by adding a booster dose. Moreover, unvaccinated patients may be persuaded to undergo vaccination.
Identifiants
pubmed: 34984646
doi: 10.1007/s15010-021-01751-1
pii: 10.1007/s15010-021-01751-1
pmc: PMC8725959
doi:
Substances chimiques
COVID-19 Vaccines
0
Vaccines
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
747-752Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
Références
Nat Rev Immunol. 2021 Oct;21(10):626-636
pubmed: 34373623
Postgrad Med J. 2022 May 1;98(1159):389-394
pubmed: 37066438
Lancet. 2021 Feb 20;397(10275):671-681
pubmed: 33545094
J Infect. 2021 Aug;83(2):e20-e21
pubmed: 34116073
Nature. 2021 Aug;596(7871):178-180
pubmed: 34354274
Nature. 2021 Aug 19;:
pubmed: 34413527
Lancet. 2021 May 15;397(10287):1819-1829
pubmed: 33964222
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Lancet. 2021 Jul 17;398(10296):213-222
pubmed: 34246358
N Engl J Med. 2021 Sep 2;385(10):875-884
pubmed: 34233097